Table 1:

Adjuvant Therapy De-escalation Trials in Progress

Name	Title	Phase	Interventions	Enrollment	Estimated Completion	Primary Outcome Measure(s)	NCT #	Study Sponsor
DART-HPV	DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer	3	Reduced RT (30 – 36 Gy, depending on risk group) + docetaxel is compared with 60 Gy +/− cisplatin	214	2024	Adverse Events Rate	NCT02908477	Mayo Clinic
PATHOS	A Phase III Trial of Risk stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus(HPV)-Positive Oropharyngeal Cancer	3	Intermediate risk group: reduced RT (50 Gy) is compared with 60 Gy; High risk group: adjuvant CRT is compared with adjuvant RT alone	1100	2026	MDADI/Overall survival co-primary endpoint	NCT02215265	Lisette Nixon
MINT	Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV Related Oropharynx Squamous Cell Carcinoma: “The Minimalist Trial(MINT)”	2	Low risk group: reduced RT (42 Gy) alone, intermediate risk group: reduced RT (42 Gy) one cisplatin dose, high risk group: standard of care (60 Gy + 3 doses cisplatin)	43	2022	Percent weight loss in patients during modified adjuvant CRT	NCT03621696	Washington University School of Medicine

Data from clinicaltrials.gov; Abbreviations- RT: radiation therapy, CRT: chemoradiation therapy, Gy: Gray, PFS: progression-free survival, MDADI:MD Anderson Dysphagia Inventory